FAPI-PET成像的最新进展:系统综述与荟萃分析
患者层面汇总灵敏度为0.99(95%CI 0.97-1.00),汇总特异度为0.87(95%CI 0.62-1.00),提示FAPI-PET在不宜行[18F]FDG成像的肿瘤(尤其原发灶与远处转移)中具有应用前景,但仍需高级别证据明确其定位。
要点
- 患者层面FAPI-PET汇总灵敏度0.99(95%CI 0.97-1.00)、汇总特异度0.87(95%CI 0.62-1.00)。
- 原发肿瘤汇总灵敏度1.00(95%CI 0.98-1.00),远处转移汇总灵敏度0.93(95%CI 0.88-0.97)。
- 病灶层面灵敏度与特异度异质性高(I2分别为88.56%和97.20%),结论需谨慎解读。
核心结论
- FAPI-PET在不宜行[18F]FDG成像的肿瘤中表现有前景,尤其是原发灶与远处转移。
- 尚需高级别证据明确其适用癌种、非肿瘤疾病及临床场景。
研究设计与样本
- 系统综述与荟萃分析,检索MedLine与Embase数据库,时间限定为2018年1月1日至2021年3月31日。
- 研究质量采用QUADAS-2标准评估,汇总灵敏度/特异度用随机效应模型经STATA「metaprop」命令直接计算,并用I2统计量检验研究间异质性。
主要发现
- 患者层面分析:汇总灵敏度0.99(95%CI 0.97-1.00),异质性可忽略;汇总特异度0.87(95%CI 0.62-1.00),异质性可忽略。
- 病灶层面分析:灵敏度与特异度异质性高(I2分别为88.56%和97.20%)。
- 原发肿瘤汇总灵敏度1.00(95%CI 0.98-1.00),异质性可忽略;淋巴结转移汇总灵敏度/特异度异质性高(I2分别为89.18%和95.74%)。
- 远处转移汇总灵敏度良好,为0.93(95%CI 0.88-0.97),异质性可忽略。
关键数值与推荐
- FAPα在约90%的上皮性肿瘤的癌相关成纤维细胞中过表达,是治疗与分子成像的靶点。
- 患者层面汇总灵敏度0.99(95%CI 0.97-1.00)、汇总特异度0.87(95%CI 0.62-1.00)。
- 原发肿瘤汇总灵敏度1.00(95%CI 0.98-1.00);远处转移汇总灵敏度0.93(95%CI 0.88-0.97)。
- 病灶层面灵敏度I2=88.56%、特异度I2=97.20%;淋巴结转移灵敏度I2=89.18%、特异度I2=95.74%。
临床怎么用
- 对不宜行[18F]FDG成像的肿瘤,可考虑FAPI-PET评估原发灶与远处转移。
- FAPI-PET的应用癌种与临床场景尚未经高级别证据确定,需结合具体病例谨慎选择。
局限性
- 纳入荟萃分析的研究数量与患者数有限(如头颈癌仅2项研究、29例患者)。
- 病灶层面及淋巴结转移分析异质性高(I2最高达97.20%)。
- 作者指出尚需高级别证据明确FAPI-PET的角色与适用范围。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Fibroblast activation protein-α (FAPα) is overexpressed on cancer-associated fibroblasts in approximately 90% of epithelial neoplasms, representing an appealing target for therapeutic and molecular imaging applications. [68 Ga]Ga-labelled radiopharmaceuticals-FAP-inhibitors (FAPI)-have been developed for PET. We systematically reviewed and meta-analysed published literature to provide an overview of its clinical role. MATERIALS AND METHODS: The search, limited to January 1st, 2018-March 31st, 2021, was performed on MedLine and Embase databases using all the possible combinations of terms "FAP", "FAPI", "PET/CT", "positron emission tomography", "fibroblast", "cancer-associated fibroblasts", "CAF", "molecular imaging", and "fibroblast imaging". Study quality was assessed using the QUADAS-2 criteria. Patient-based and lesion-based pooled sensitivities/specificities of FAPI PET were computed using a random-effects model directly from the STATA "metaprop" command. Between-study statistical heterogeneity was tested (I2-statistics). RESULTS: Twenty-three studies were selected for systematic review. Investigations on staging or restaging head and neck cancer (n = 2, 29 patients), abdominal malignancies (n = 6, 171 patients), various cancers (n = 2, 143 patients), and radiation treatment planning (n = 4, 56 patients) were included in the meta-analysis. On patient-based analysis, pooled sensitivity was 0.99 (95% CI 0.97-1.00) with negligible heterogeneity; pooled specificity was 0.87 (95% CI 0.62-1.00), with negligible heterogeneity. On lesion-based analysis, sensitivity and specificity had high heterogeneity (I2 = 88.56% and I2 = 97.20%, respectively). Pooled sensitivity for the primary tumour was 1.00 (95% CI 0.98-1.00) with negligible heterogeneity. Pooled sensitivity/specificity of nodal metastases had high heterogeneity (I2 = 89.18% and I2 = 95.74%, respectively). Pooled sensitivity in distant metastases was good (0.93 with 95% CI 0.88-0.97) with negligible heterogeneity. CONCLUSIONS: FAPI-PET appears promising, especially in imaging cancers unsuitable for [18F]FDG imaging, particularly primary lesions and distant metastases. However, high-level evidence is needed to define its role, specifically to identify cancer types, non-oncological diseases, and clinical settings for its applications.
引用
- Sollini M, Kirienko M, Gelardi F, et al. State-of-the-art of FAPI-PET imaging: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2021. PMID: 34173007. doi:10.1007/s00259-021-05475-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。